ArticleFrontiers in oncology2026
Temporal trends, disparities, and ARIMA forecasts of mortality among U.S. adults with coexisting hematologic malignancy and heart failure, 1999-2023, with projections to 2033.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematologic malignancies (HMs) and heart failure (HF) increasingly coexist as populations age, yet population-level mortality patterns in adults with both conditions remain poorly defined. We characterized long-term temporal trends and demographic disparities in HM-HF mortality and forecasted future rates through predictive modeling. Methods: We analyzed U.S. multiple cause-of-death data (1999-2023) for adults aged ≥45 years with both HMs and HF listed on death certificates. Age-adjusted mortality rates (AAMRs) were calculated per 100,000 population. Joinpoint regression was used to identify changes in temporal trends, with analyses stratified by demographics, HM subtype, and geography. Autoregressive integrated moving average (ARIMA) modeling was applied to project mortality trends through 2033. Results: Among 119,147 deaths, the overall AAMR was 3.96 per 100,000 (95% CI, 3.85-4.07). Joinpoint analysis identified four phases: a significant decline from 1999 to 2013 (annual percent change [APC] -1.97%), a plateau from 2013 to 2018, a sharp increase from 2018 to 2021 (APC + 8.35%), and subsequent stabilization from 2021 to 2023. Mortality was 85% higher in males than females (5.47 vs. 2.95 per 100,000). Rates increased markedly with age, with adults aged ≥85 years showing the steepest rise after 2014 (APC + 5.75%). Non-Hispanic Black and non-Hispanic White populations had the highest absolute AAMRs. All HM subtypes demonstrated a similar decline-rebound pattern, with subtype-specific differences in the timing of inflection points. ARIMA projections suggested a gradual decline from 4.78 per 100,000 in 2024 to 3.77 per 100,000 by 2033. Conclusions: HM-HF mortality declined through 2013 but reversed in the late 2010s, with pronounced increases during 2018-2021 followed by recent stabilization. Persistent disparities by sex, age, race/ethnicity, and geography highlight the need for targeted interventions and strengthened cardio-oncology capacity for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.